EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis

Yubiao Pan iD, Yue Wang iD, Yaqin Xiong, Panpan Li iD, Chenqi Yu iD, Peng Liu iD

Hematological Oncology · 2026

DOI: 10.1002/hon.70234 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Yubiao Pan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunoglobulin Light Chains, Neoplasm, Residual. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Minimal residual disease (MRD) is the standard for deep response assessment in multiple myeloma but requires bone marrow sampling. Whether early serum free light chain (sFLC) response provides independent prognostic information in real‐world, predominantly non‐transplant patients remains unclear. We retrospectively analyzed 701 patients with newly diagnosed multiple myeloma treated at a single Chinese center (2015–2021). sFLC ratio normalization (IMWG range 0.26–1.65) during the first four induction cycles was assessed using a 4‐month landmark to mitigate immortal time bias. Multivariable Cox models adjusted for R‐ISS and age, with prespecified sensitivity analyses and direct comparison with established markers and MRD. Among 701 patients (median age 64 years; ASCT 12.6%), 433 (61.8%) were classified as FLC‐normalized during C1‐C4. FLC non‐normalization was associated with inferior PFS (HR 2.10, 95% CI 1.60–2.76) and OS (HR 1.96, 95% CI 1.32–2.90) after adjustment for R‐ISS stage and age. The association persisted in baseline‐abnormal patients and after MRD adjustment. Adding sFLC status produced a modest improvement in model discrimination, supporting a complementary rather than stand‐alone prognostic role. sFLC normalization was documented earlier than MRD negativity, a pattern that persisted in a paired‐visit‐restricted sensitivity analysis, although timing comparisons remain subject to retrospective assessment schedules. Early sFLC response was associated with outcomes in newly diagnosed multiple myeloma and provided complementary, incremental prognostic information beyond established risk factors and MRD. These findings support further prospective evaluation of sFLC normalization as a pragmatic blood‐based marker for early risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunoglobulin Light ChainsNeoplasm, ResidualHumansPrognosisRetrospective StudiesFemaleMaleMiddle AgedAgedAdultBiomarkers, Tumor

Stichwörter der Autor:innen

induction therapyminimal residual diseasemultiple myelomaprognostic biomarkerserum free light chains

Substanzen

Immunoglobulin Light ChainsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, China.

ORCID-Profile: Yubiao Pan, Yue Wang, Panpan Li, Chenqi Yu, Peng Liu

Förderung

  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Pan, Y., Wang, Y., Xiong, Y., Li, P., Yu, C., & Liu, P. (2026). Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis. Hematological Oncology. https://doi.org/10.1002/hon.70234

Vancouver

Pan Y, Wang Y, Xiong Y, Li P, Yu C, Liu P. Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis. Hematological Oncology. 2026. doi:10.1002/hon.70234

BibTeX
@article{Pan2026,
  author = {Pan, Yubiao and Wang, Yue and Xiong, Yaqin and Li, Panpan and Yu, Chenqi and Liu, Peng},
  title = {Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70234}
}
Kostenlos starten →